TY - JOUR
T1 - Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis
AU - Kimura, Akio
AU - Takemura, Masao
AU - Serrero, Ginette
AU - Yoshikura, Nobuaki
AU - Hayashi, Yuichi
AU - Saito, Kuniaki
AU - Inuzuka, Takashi
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS − )], 21 with carcinomas (10 CNS + ; 11 CNS − ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS − lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS − carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS − lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS − carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS − diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.
AB - Assessing central nervous system (CNS) involvement in patients with lymphoma or carcinoma is important in determining therapy and prognosis. Progranulin (PGRN) is a secreted glycosylated protein with roles in cancer growth and survival; it is highly expressed in aggressive cancer cell lines and specimens from many cancer types. We examined PRGN levels by Enzyme Immuno-Assay (EIA) in cerebrospinal fluid (CSF) samples from 230 patients, including 18 with lymphoma [12 with CNS metastasis (CNS + ); 6 without CNS metastasis (CNS − )], 21 with carcinomas (10 CNS + ; 11 CNS − ), and 191 control patients with non-cancer neurological diseases, and compared PRGN levels among these disease groups. Median CSF PGRN levels in the CNS + lymphoma group were significantly higher than in the CNS − lymphoma and control non-cancer groups; and were also significantly higher in the CNS + carcinoma group than in the CNS − carcinoma and control groups, except for patients with infectious neurological disorders. Receiver operating characteristic curve analyses revealed that CSF PGRN levels distinguished CNS + lymphoma from CNS − lymphoma and non-cancer neurological diseases [area under curve (AUC): 0.969]; and distinguished CNS + carcinomas from CNS − carcinomas and non-cancer neurological diseases (AUC: 0.918). We report here, for the first time, that CSF PGRN levels are higher in patients with CNS + lymphoma and carcinomas compared to corresponding CNS − diseases. This would imply that measuring CSF PGRN levels could be used to monitor CNS + lymphoma and metastasis.
UR - http://www.scopus.com/inward/record.url?scp=85042767843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042767843&partnerID=8YFLogxK
U2 - 10.1007/s11060-017-2742-z
DO - 10.1007/s11060-017-2742-z
M3 - Article
C2 - 29340960
AN - SCOPUS:85042767843
SN - 0167-594X
VL - 137
SP - 455
EP - 462
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 3
ER -
